Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Barbara M. Grüner

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0974-4826; OpenAlex author ID A5025856946. Sources: funder_awards.

Their work

Papers
8 (first author 0, last author 3)
Trials
0
Grants
1
Labs led
1
Collaborators
36
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 grant · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. Loss of the Y chromosome drives basal identity and metastatic potential via epigenetic reprogramming in pancreatic cancer Last author DOI 10.64898/2026.10.06.756936↗
  2. PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2025.115541↗
  3. Unraveling Tumor Heterogeneity by Using DNA Barcoding Technologies to Develop Personalized Treatment Strategies in Advanced-Stage PDAC. Last author DOI 10.3390/cancers13164187↗
  4. Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Last author DOI 10.1038/s41598-018-32159-x↗
  5. BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-17-0250↗
  6. Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-15-0165↗
  7. Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing. Co-author DOI 10.1101/gad.264861.115↗
  8. MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0039424↗

Grants 1

  1. Multiplexed in vivo drug screening: Inhibitors of metastatic seeding AWARD pancan:2014-barbara-gr-ner-phd-multiplexed-in-vivo-drug-screening-inhib

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Madeleine Dorsch · 3 shared papers, 2018–2026 · strength 0.48
  2. Jens Thomas Siveke · 4 shared papers, 2012–2026 · strength 0.47
  3. Laura Godfrey · 2 shared papers, 2025–2026 · strength 0.40
  4. Marija Trajkovic‐Arsic · 2 shared papers, 2012–2025 · strength 0.23
  5. Rui Fang · 1 shared paper, 2025 · strength 0.20
  6. Hendrik Schürmann · 1 shared paper, 2025 · strength 0.20
  7. Stephan A. Hahn · 1 shared paper, 2025 · strength 0.20
  8. Ben Zhao · 1 shared paper, 2025 · strength 0.20
  9. Smiths Lueong · 1 shared paper, 2025 · strength 0.20
  10. Barbara T. Grünwald · 1 shared paper, 2026 · strength 0.20
  11. Kazeera Aliar · 1 shared paper, 2026 · strength 0.20
  12. Günter Schneider · 1 shared paper, 2026 · strength 0.20
  13. John P. Neoptolemos · 1 shared paper, 2026 · strength 0.20
  14. Elisabeth Heßmann · 1 shared paper, 2026 · strength 0.20
  15. Faiyaz Notta · 1 shared paper, 2026 · strength 0.20
  16. Philip Dujardin · 1 shared paper, 2021 · strength 0.19
  17. Shin‐Heng Chiou · 3 shared papers, 2015–2018 · strength 0.18
  18. Monte Meier Winslow · 3 shared papers, 2015–2018 · strength 0.18
  19. Albert C. Koong · 2 shared papers, 2017–2018 · strength 0.14
  20. Margaret M. Kozak · 2 shared papers, 2017–2018 · strength 0.14
  21. Grace Kim · 2 shared papers, 2015–2017 · strength 0.10
  22. Axel Karl Walch · 2 shared papers, 2012–2016 · strength 0.08
  23. Roland Michael Schmid · 2 shared papers, 2012–2016 · strength 0.08
  24. Iréne Esposito · 2 shared papers, 2012–2016 · strength 0.08
  25. Amato J. Giaccia · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.